Etanercept-induced hypoglycemia and improved glycemic control in a patient with type 2 diabetes

Endocrine Practice

Volumn 17, Issue 2, 2011, Pages 306-307

  Farrokhi, Farnoosh ^a   Taylor, Harris C ^a   McBride, Nancy M ^a  

^a FAIRVIEW HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ETANERCEPT; GLIBENCLAMIDE; METFORMIN; ROSIGLITAZONE;

ADULT; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PSORIASIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 79959266420     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Martinez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M. Effect of etaner-cept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299:461-465. (Pubitemid 47546924)
2. Bonilla E, Lee YY, Phillips PE, Perl A. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis. 2007;66:1688. (Pubitemid 350205467)
3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. (Pubitemid 12149145)